Ginkgo Bioworks Holdings, Inc.

0001830214 FALSE 0001830214 2026-05-07 2026-05-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 8-K ______________________________________________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2026 ______________________________________________________________ GINKGO BIOWORKS HOLDINGS, INC. (Exact name of registrant as specified in its charter) ______________________________________________________________ Delaware 001-40097 87-2652913 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 27 Drydock Avenue 8th Floor Boston , MA 02210 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: ( 877 ) 422-5362 (Former name or former address, if changed since last report) ______________________________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act Title of each class Trading Symbol(s) Name of each exchange on which registered Class A common stock, par value $0.0001 per share DNA NYSE Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02. Results of Operations and Financial Condition. On May 7, 2026, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, issued by Ginkgo Bioworks Holdings, Inc. on May 7 , 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GINKGO BIOWORKS HOLDINGS, INC. Date: May 7, 2026 By: /s/ Steven Coen Name: Steven Coen Title: Chief Financial Officer